• 1.

    Levin A, et al.. Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. Lancet 2017; 390:18881917.

  • 2.

    KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; [Suppl 3]:1150.

  • 3.

    Coresh J, et al.. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311:25182531.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Tangri N, et al.. Multinational assessment of accuracy of equations for predicting risk of kidney failure: A meta-analysis. JAMA 2016; 315:164174.

  • 5.

    Porrini E, et al.. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diab Endocrinol 2015; 3:382391.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Federico G, et al.. Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis. J Clin Invest Insight 2016; 1:e84916.

  • 7.

    Zewinger S, et al.. Dickkopf-3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J Am Soc Nephrol 2018; 29:27222733.

  • 8.

    Rauen T, et al.. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:22252236.

Identifying Patients at High Risk for Short-Term Chronic Kidney Disease Progression: Still a Challenge?

  • 1 Danilo Fliser, MD, is associated with the Department of Internal Medicine IV, Saarland University Medical Center, Homburg/Saar, Germany.
Restricted access